<DOC>
	<DOCNO>NCT02498444</DOCNO>
	<brief_summary>The purpose study test efficacy treprostinil perioperative non-fenestrated , extracardiac Fontan patient order reduce duration chest tube drainage ( day ) . The Fontan operation perform patient single ventricle physiology final palliation create series circulation , passive systemic venous return pulmonary artery single ventricle solely provide systemic output . Patients undergoing extracardiac Fontan tend elevation Fontan pressure immediately following operation inflammation surgery require additional fluid administration maintain blood pressure . Increased Fontan pressure fluid overload lead prolong chest tube drainage . The hypothesis treprostinil , prostacyclin drug dilates pulmonary artery , improve immediate postoperative Fontan pressure . Treprostinil FDA approve use . Anecdotally small case series , prostacyclin therapy show assist transition patient nitric oxide . The investigator believe improvement hemodynamics decrease duration chest tube drainage result short length hospital stay .</brief_summary>
	<brief_title>Perioperative Treprostinil Pediatric Patients Undergoing Fontan Operation</brief_title>
	<detailed_description>In order understand effect treprostinil Fontan patient , study two part : 1. reactivity test inhaled treprostinil cardiac catheterization lab pre-Fontan patient undergo routine catheterization anticipation Fontan operation ; 2. perioperative use subcutaneous treprostinil start immediately pre-op postoperative day # 7 improve immediate postoperative hemodynamics ultimately reduce overall length hospital stay . The investigator hope learn pulmonary vasodilator therapy affect and/or improves post- operative hemodynamics follow Fontan operation . This knowledge would important care single ventricle patient follow Fontan operation improvement immediate outcome reduction hospital length stay . On broad scale , use treprostinil perioperative Fontan patient achieve result center achieve use fenestration may wide scale implication nationwide treatment Fontan patient .</detailed_description>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Pediatric patient undergo Fontan operation and/or preFontan cardiac catheterization Lucile Packard Children 's Hospital ( LPCH ) Platelet count &lt; 50K ( treprostinil act platelet inhibitor may place patient additional risk bleed already thrombocytopenic ) Dermatologic condition render patient unable tolerate subcutaneous infusion ( still take part inhale vasodilator test cardiac catheterization ) Currently receive vasodilator therapy specifically purpose pulmonary vsasodilation ( phosphodiesterase type 5 inhibitor , endothelia receptor antagonist and/or prostacyclin ) .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fontan</keyword>
	<keyword>Treprostinil</keyword>
	<keyword>Remodulin</keyword>
	<keyword>Single ventricle</keyword>
</DOC>